

---

## AAE-581

产品编号: D51007

CAS: 354813-19-7

分子式: C<sub>23</sub>H<sub>33</sub>N<sub>5</sub>O<sub>2</sub>

纯度: ≥98%

InChi: InChi=1S/C<sub>23</sub>H<sub>33</sub>N<sub>5</sub>O<sub>2</sub>/c1-2-14-27-15-17-28(18-16-27)20-8-6-19(7-9-20)21(29)26-23(10-4-3-5-11-23)22(30)25-13-12-24/h6-9H,2-5,10-11,13-18H<sub>2</sub>,1H<sub>3</sub>, (H,25,30)(H,26,29)

InChi Key: LLCRBOWRJOUJAE-UHFFFAOYSA-N

Smiles: CCCN1CCN(CC1)C1=CC=C(C=C1)C(=O)NC1(CCCCC1)C(=O)NCC#N

外观: 固体粉末

作用通路: Cathepsin

溶解性: DMSO: ≥46 mg/mL

保存条件: Store in dry, dark place for one year.

产品介绍: Balicatib(AAE-581) is a potent and selective inhibitor of cathepsin K; 10-100 fold more potent in cell-based enzyme occupancy assays than against cathepsin B, L, and S. IC<sub>50</sub> value:  
Target: cathepsin K The cathepsin K inhibitor AAE-581 (balicatib) as the most advanced of them passed Phase II clinical trials in 2005. Eighty adult female *Macaca fascicularis* underwent bilateral ovariectomies and were dosed twice daily by oral gavage with balicatib at 0, 3, 10, and 50 mg/kg for 18 months (groups O, L, M, H, respectively). Approximately 1 month after treatment initiation, the 50 mg/kg dose was decreased to 30 mg/kg. Twenty animals underwent sham-ovariectomies (group S). Bone mass was measured at 3-6 month intervals. At 18 months, vertebra and femur were collected for histomorphometry.